US EditionPublished • loading... • Updated
New Study Offers Hope for People With Drug-Resistant Epilepsy
A clinical trial showed XEN1101 reduced monthly seizures by 33% to 53% in treatment-resistant focal epilepsy patients, with 18% seizure free after six months, researchers said.
- On Oct. 22, 2025, NYU Langone Health researchers found nearly 70% of treatment-resistant adults with focal epilepsy reduced monthly seizures over time after monitoring nearly 150 patients for up to three years.
- Because about one-third of patients with focal epilepsy fail first-line therapies, NYU Langone Health researchers studied treatment-resistant patients who tried at least four anti-seizure medications.
- Led by researchers at NYU Grossman School of Medicine, the XEN1101 trial showed a 33% to 53% drop in monthly seizures versus placebo's 18%, with no dangerous heart or skin problems reported.
- Study authors urged health care providers to keep searching for effective regimens as failed prior drugs do not rule out improvement, and the team plans to expand studies in the next stage of the Human Epilepsy Project.
- The study notes that patients who improved often used newer drugs such as cenobamate, clobazam, eslicarbazepine and epidiolex, all approved within the past 15 years.
Insights by Ground AI
28 Articles
28 Articles
The Norfolk Daily News+25 Reposted by 25 other sources
New Study Offers Hope for People With Drug-Resistant Epilepsy
Key Takeaways
New drug offers relief for treatment-resistant epilepsy patients
In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows. Unlike several treatments that must be started at low doses and slowly ramped up, the new drug can safety be taken at its most effective dose from the start, the authors say.
·United States
Read Full Article
Coverage Details
Total News Sources28
Leaning Left6Leaning Right4Center7Last UpdatedBias Distribution41% Center
Bias Distribution
- 41% of the sources are Center
41% Center
L 35%
C 41%
R 24%
Factuality
To view factuality data please Upgrade to Premium
